Work

A digital SERS platform powered by bispecific antibody fragments for SARS-CoV-2 diagnostics

Year: 2025

Type: article

Abstract: Surface-enhanced Raman scattering (SERS) immunoassays are powerful analytical tools for protein detection while typically rely on the availability of suitable antibodies. Compared to full-length antibodies, antibody fragments provide advantages such as rapid and cost-effective production. However, oriented conjugation of antibody fragments to SERS nanotags, essential for maintaining their functionality, remains relatively underexplored. Here, we introduce a bispecific antibody (BsAb)-programmable digital immunochemistry detection regime implemented on an advanced digital SERS platform (“DigibiSERS”), enabling deterministic molecular orientation, variance‐robust single‐particle event calling, and kinetic regularization within one unified platform. Specifically, we fuse an anti-nucleocapsid nanobody with a single-chain variable fragment targeting methoxy polyethylene glycol (mPEG) grafted onto the SERS nanotag surfaces. This design facilitates straightforward, oriented BsAb conjugation, preserving its functionality. The DigibiSERS platform, incorporating single-particle active SERS nanotags, nanomixing-enhanced microchips, and digital readouts, demonstrates high sensitivity and specificity, achieving detection limits of 2.01 ng/mL for nucleocapsid protein and 2.7 copies/mL for virus. An area under the curve (AUC) of 0.8783 highlights the potential of engineered antibody fragments in enhancing the clinical sensitivity and practicality of SERS-based immunoassays for infectious disease diagnostics. • Novel probe design: To our knowledge, this is the first demonstration of BsAb-functionalized SERS nanotags , enabling noncovalent and orientation-controlled conjugation for improved assay fidelity. • Integrated digital immunoassay: Combining BsAb nanotags with nanomixing-enhanced microfluidics and digital readout improved sensitivity, signal uniformity, and reproducibility. • Clinical validation: We demonstrate accurate discrimination between SARS-CoV-2-positive and healthy individuals using clinical swab samples, underscoring the translational relevance of this approach.

Source: Biosensors and Bioelectronics

DOI: 10.1016/j.bios.2025.118252

Authors: Jing Wang, Quan Zhou, Kym Lowry, Christopher B. Howard, Matt Trau

Institutions: Fujian Normal University, The University of Queensland, Royal Brisbane and Women's Hospital, Children's Health Queensland Hospital and Health Service

Language: English

Topic: SARS-CoV-2 detection and testing

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,540